{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antiretroviral+Regimens&page=3", "query": { "intervention": "Antiretroviral Regimens", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 238, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antiretroviral+Regimens&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antiretroviral+Regimens&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T16:32:41.325Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02951052", "title": "Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "Cabotegravir (CAB) tablet", "type": "DRUG" }, { "name": "Rilpivirine (RPV) tablet", "type": "DRUG" }, { "name": "Cabotegravir - Injectable Suspension (CAB LA)", "type": "DRUG" }, { "name": "Rilpivirine - Injectable Suspension (RPV LA)", "type": "DRUG" }, { "name": "2 NRTIs plus an INI, NNRTI, or PI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 618, "start_date": "2016-10-28", "completion_date": "2029-12-31", "has_results": true, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-09T16:32:41.325Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02951052" }, { "nct_id": "NCT02120352", "title": "A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "CAB Oral Tablets", "type": "DRUG" }, { "name": "CAB LA", "type": "DRUG" }, { "name": "ABC/3TC Oral tablets", "type": "DRUG" }, { "name": "RPV Oral Tablets", "type": "DRUG" }, { "name": "HAART", "type": "OTHER" }, { "name": "RPV", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 309, "start_date": "2014-04-28", "completion_date": "2023-04-20", "has_results": true, "last_update_posted_date": "2024-06-12", "last_synced_at": "2026-10-09T16:32:41.325Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02120352" }, { "nct_id": "NCT00336778", "title": "Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "3TC, TDF, NLV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2004-01", "completion_date": "2008-04", "has_results": false, "last_update_posted_date": "2021-05-11", "last_synced_at": "2026-10-09T16:32:41.325Z", "location_count": 2, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00336778" }, { "nct_id": "NCT02641444", "title": "Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV" ], "interventions": [ { "name": "Blood plasma collection", "type": "PROCEDURE" }, { "name": "Cervical and Vaginal Biopsy", "type": "PROCEDURE" }, { "name": "Colonoscopy with Ileal and Rectal Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 5, "start_date": "2016-04-13", "completion_date": "2017-08-29", "has_results": false, "last_update_posted_date": "2018-01-17", "last_synced_at": "2026-10-09T16:32:41.325Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02641444" }, { "nct_id": "NCT00296504", "title": "A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "fosamprenavir (GW433908)", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 753, "start_date": "2001-11", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2013-04-19", "last_synced_at": "2026-10-09T16:32:41.325Z", "location_count": 10, "location_summary": "Fountain Valley, California • San Francisco, California • Denver, Colorado + 6 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00296504" }, { "nct_id": "NCT00002410", "title": "A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dupont Merck", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "13 Years to 60 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-09T16:32:41.325Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002410" }, { "nct_id": "NCT00814879", "title": "Pilot Study of a Raltegravir Based NRTI Sparing Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acquired Immune Deficiency Syndrome", "AIDS", "Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "Raltegravir", "type": "DRUG" }, { "name": "Atazanavir", "type": "DRUG" }, { "name": "Standard treatment regimen", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2009-05", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2016-02-04", "last_synced_at": "2026-10-09T16:32:41.325Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Waterbury, Connecticut • West Haven, Connecticut + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Waterbury", "state": "Connecticut" }, { "city": "West Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00814879" }, { "nct_id": "NCT02422797", "title": "Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DTG 50 mg", "type": "DRUG" }, { "name": "RPV 25 mg", "type": "DRUG" }, { "name": "CAR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 518, "start_date": "2015-04-21", "completion_date": "2023-05-25", "has_results": true, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-10-09T16:32:41.325Z", "location_count": 13, "location_summary": "Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Vero Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02422797" }, { "nct_id": "NCT00700115", "title": "Kaletra-isentress Treatment Evaluation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Kaletra + Isentress", "type": "DRUG" }, { "name": "Pre-study antiretroviral regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2008-06", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2014-12-12", "last_synced_at": "2026-10-09T16:32:41.325Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00700115" }, { "nct_id": "NCT00224445", "title": "Boosted Atazanavir and Truvada Given Once-Daily - BATON Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Truvada", "type": "DRUG" }, { "name": "Atazanavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2005-09", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2013-01-10", "last_synced_at": "2026-10-09T16:32:41.325Z", "location_count": 1, "location_summary": "Foster City, California", "locations": [ { "city": "Foster City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00224445" } ] }